NFKB1 and B-cell chronic lymphocytic leukemia: Additionally, recent studies demonstrate that both natural and synthetic inhibitors targeting MYD88 can effectively disrupt NF-κB signaling and exhibit anti-inflammatory and anti-cancer effects, which could indicate the importance of understanding its role in the progression of CLL to RS [60].